Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure

NCT07038356 is registered in ClinicalTrials.gov with Christian Schulze as lead sponsor.

NCT NCT07038356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07038356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Continued Administration of Empagliflozin in Patients With Heart Failure on Active SGLT2 Inhibitor Treatment Admitted for Acute Decompensated Heart Failure
Lead sponsor
Christian Schulze
Phase
Phase 3
Overall status
Recruiting
Start date
December 8, 2025
Completion date
June 30, 2027
Enrollment
536 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

acute decompensated heart failure (adhf)